![](https://media.asiaone.com/sites/default/files/styles/a1_600x316/public/original_images/Jul2024/ACN%20Newswire_0.png?h=ec041e41&itok=s3QIPiTE)
"LEQEMBI" Lecanemab) Approved for the Treatment of Alzheimer's Disease in Israel
TOKYO and CAMBRIDGE, Mass., July 12, 2024 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody “LEQEMBI®” (generic name: lecanemab) has been approved in Israel as a …